Eir Ventures

The Nordic Star Pitch Competition has officially launched 🚀 Twenty pre-selected Nordic companies are presenting their pitches to a distinguished jury and a captivated audience. The energy and excitement in the room are palpable! 🔗 The selected companies: https://lnkd.in/dBJFXbx9 The jury: Mandeep Dhillon, Johnson & Johnson Sara Kangaspeska, Innovestor Markus Dietrich, PhD, Hadean Ventures Inka Mero, Voima Ventures Chloé Leprêtre, Servier Lovisa Backemar, Eir Ventures Marjo Puumalainen, SwedenBIO #NLSDays #lifescience #Nordic #startup

Congratulation to our portfolio company IO Biotech on the gret phase 2 data from their study of the effects of their lead candidate IO102-IO103 in scuamous cell carcinoma

HONORARY AWARD TO PROFESSOR GREGOR JEMEC 🏆 We are proud to announce that Professor of Dermatology and Head of Research at Sjællands Universitetshospital/Zealand University Hospital, Gregor Jemec, has been honored with the LEO Foundation Anniversary Prize of DKK 5 million (EUR 670,500). He receives the award for his extraordinary contribution to skin research, especially his pioneering and persistent work on hidradenitis suppurativa (HS) – a chronic and debilitating skin disease. “Gregor Jemec is awarded with the LEO Foundation Anniversary Prize for his visionary and substantial research in the skin and its diseases. Gregor Jemec is not only an excellent, committed and internationally respected scientist. He is also among the 10 most cited dermatologists in the world as well as the most cited within HS. His persistence and merits are extraordinary, which is why we are proud to award Gregor Jemec with this honorary prize,” says Professor Peter Schwarz, member of the LEO Foundation Board of Trustees and Chairman of the Foundation’s Grant Committee. Warmest congratulations from the LEO Foundation 💐

We thrilled to officially announce the pioneering companies selected for the BIO-X Accelerate program! Congratulations to: 🌟 ArgusEye – Revolutionizing bioprocessing with advanced biosensors. 🌟 Rarity Bioscience – Pioneering precision cancer diagnostics. 🌟 Readily Diagnostics – Developing rapid and impactful diagnostic tests. 🌟 Phenaros Pharmaceuticals – Innovative drug development. 🌟 Strike Pharma AB – Taking precision medicine to a new level. “We are very pleased to welcome these five innovative companies to the BIO-X Accelerate program. Previous rounds have shown that our support has contributed to companies attracting significant investment and taking important steps forward in their development. With the new participants, we look forward to continuing to drive innovation in life science and health, and contribute to a sustainable and digital transformation." – Dajana I., Project Manager for the BIO-X Accelerate program at STUNS. BIO-X Accelerate was initiated in 2020 with the goal of facilitating the transition of small and medium-sized enterprises within the region’s life science sector from the early stages to a rapid phase of innovation and growth. The project aimed to enhance the competitiveness of these companies by generating innovative products that have high demand in the global healthcare market. The BIO-X Accelerate program will be in progress during 2024-2026 with these companies and the new theme “IMPACT”. Read the full press release👇 https://lnkd.in/dFN99UQV This project is funded by The European Regional Development Fund (ERDF) via Tillväxtverket. Thanks to our strategic and supporting partners: UIC - Uppsala Innovation Centre, Connect Sverige Region Uppsala, LEAD (Business Incubator), Inkubera, Create Business Incubator, Linköpings universitet, Uppsala universitet and Örebro universitet Holding. #Uppsala #Lifescience #Innovation

IO Biotech announced today that an Independent Data Monitoring Committee recommended continuation of the company’s pivotal Phase 3 trial of its lead investigational therapeutic vaccine, IO102-IO103, without modifications following a per-protocol interim analysis.   Read the full press release here: https://bit.ly/4cM8XFu